CHRONIC USE OF PROTON PUMP INHIBITORS AND THE QUANTITY OF G, D, AND ECL CELLS IN THE STOMACH

Overview

Journal Arq Bras Cir Dig

Specialties Gastroenterology
General Surgery

Date 2020 Aug 27

PMID 32844883

Authors

Silvia Maria Perrone Camilo

Elia Claudia de Souza Almeida

Jacqueline Batista Sousa

Luana Perrone Camilo

Renata Margarida Etchebehere

Affiliations

Soon will be listed here.

Abstract

Background: Acid inhibition from chronic proton pump inhibitor use and a possible increase in gastrin can lead to changes in the regulation of hydrochloric acid production. However, it has not known whether such chronic use changes the presence of gastrin, delta, and enterochromaffin-like cells in the stomach or the relationship between gastrin and delta cells.

Aim: To analyze the number of gastrin-producing gastrin cells, somatostatin-producing cells, and histamine-producing cells in patients who were chronic users of proton pump inhibitor, with or without related Helicobacter pylori infection.

Methods: Biopsies from 105 patients, including 81 chronic proton pump inhibitor users (experimental group) and 24 controls, were processed immunohistochemically and subjected to counting of gastrin, delta, and enterochromaffin-like cells in high-magnification microscopic fields and in 10 glands.

Results: Gastrin cell, delta cell, and enterochromaffin-like cells counts were similar across the groups and appeared to be unaffected by Helicobacter pylori infection. The ratio between gastrin cells and delta cells was higher in the chronic users of proton pump inhibitor group than in controls.

Conclusion: Chronic users of proton pump inhibitor does not affect gastrin cell, delta cell, and enterochromaffin-like cell counts significantly, but may alter the ratio between gastrin cells and delta cells.

References

Fave G, Marignani M, Moretti A, DAmbra G, Martino G, Annibale B . Hypergastrinemia and enterochromaffin-like cell hyperplasia. Yale J Biol Med. 1999; 71(3-4):291-301. PMC: 2578981. View

Cheung K, Leung W . Long-term use of proton-pump inhibitors and risk of gastric cancer: a review of the current evidence. Therap Adv Gastroenterol. 2019; 12:1756284819834511. PMC: 6415482. DOI: 10.1177/1756284819834511. View

Hirasawa N . Expression of Histidine Decarboxylase and Its Roles in Inflammation. Int J Mol Sci. 2019; 20(2). PMC: 6359378. DOI: 10.3390/ijms20020376. View

Creutzfeldt W, Lamberts R, Stockmann F, Brunner G . Quantitative studies of gastric endocrine cells in patients receiving long-term treatment with omeprazole. Scand J Gastroenterol Suppl. 1989; 166:122-8; discussion 138-9. DOI: 10.3109/00365528909091259. View

Xie Y, Bowe B, Li T, Xian H, Yan Y, Al-Aly Z . Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open. 2017; 7(6):e015735. PMC: 5642790. DOI: 10.1136/bmjopen-2016-015735. View

Oberg K . Gastric neuroendocrine cells and secretory products. Yale J Biol Med. 1999; 71(3-4):149-54. PMC: 2578979. View

Huang H, Li Y, Liang J, Finkelman F . Molecular Regulation of Histamine Synthesis. Front Immunol. 2018; 9:1392. PMC: 6019440. DOI: 10.3389/fimmu.2018.01392. View

Prinz C, Zanner R, Gratzl M . Physiology of gastric enterochromaffin-like cells. Annu Rev Physiol. 2002; 65:371-82. DOI: 10.1146/annurev.physiol.65.092101.142205. View

Kim J, Park H, Cho J, Lee K, Lee S, Park I . Relationship of CagA to serum gastrin concentrations and antral G, D cell densities in Helicobacter pylori infection. Yonsei Med J. 1999; 40(4):301-6. DOI: 10.3349/ymj.1999.40.4.301. View

10.

Pohl D, Fox M, Fried M, Goke B, Prinz C, Monnikes H . Do we need gastric acid?. Digestion. 2008; 77(3-4):184-97. DOI: 10.1159/000142726. View

11.

Arnold R, Koop H . Omeprazole: long-term safety. Digestion. 1989; 44 Suppl 1:77-86. DOI: 10.1159/000200107. View

12.

Arroyo Villarino M, Lanas Arbeloa A, Esteva Diaz F, Ortego Fernandez de Retana J, Sainz Samitier R . Effects of long-term treatment with lansoprazole and omeprazole on serum gastrin and the fundic mucosa. Rev Esp Enferm Dig. 1997; 89(5):347-56. View

13.

Lamberts R, Creutzfeldt W, Stockmann F, Jacubaschke U, Maas S, Brunner G . Long-term omeprazole treatment in man: effects on gastric endocrine cell populations. Digestion. 1988; 39(2):126-35. DOI: 10.1159/000199615. View

14.

Waldum H, Sordal O, Mjones P . The Enterochromaffin-like [ECL] Cell-Central in Gastric Physiology and Pathology. Int J Mol Sci. 2019; 20(10). PMC: 6567877. DOI: 10.3390/ijms20102444. View

15.

Burkitt M, Varro A, Pritchard D . Importance of gastrin in the pathogenesis and treatment of gastric tumors. World J Gastroenterol. 2008; 15(1):1-16. PMC: 2653300. DOI: 10.3748/wjg.15.1. View

16.

Troncon L, Barbosa A, Romanello L, Toppa N . Antral gastrin cell population in patients with chagasic megaesophagus and megacolon. Braz J Med Biol Res. 1994; 27(3):645-53. View

17.

Mott C, Guarita D, Sipahi A, Betarello A . [Gastro-entero-pancreatic hormones in patients with chronic Chagas' disease]. Rev Hosp Clin Fac Med Sao Paulo. 1989; 44(2):63-72. View

18.

Frick C, Martin H, Bruder J, Lang K, Breer H . Topographic distribution pattern of morphologically different G cells in the murine antral mucosa. Eur J Histochem. 2017; 61(3):2810. PMC: 5658698. DOI: 10.4081/ejh.2017.2810. View

19.

Lundell L, Havu N, Miettinen P, Myrvold H, Wallin L, Julkunen R . Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial. Aliment Pharmacol Ther. 2006; 23(5):639-47. DOI: 10.1111/j.1365-2036.2006.02792.x. View

20.

Tsolakis A, Grimelius L, Granerus G, Stridsberg M, Falkmer S, Janson E . Histidine decarboxylase and urinary methylimidazoleacetic acid in gastric neuroendocrine cells and tumours. World J Gastroenterol. 2015; 21(47):13240-9. PMC: 4679755. DOI: 10.3748/wjg.v21.i47.13240. View